Last updated: July 28, 2026
Executive summary: PREZISTA (darunavir) is the top-selling protease inhibitor in its class and is marketed in multiple oral solid and suspension formats (notably tablets and oral suspension). Commercial opportunity is concentrated in (1) new darunavir oral dosage forms that improve solubility or pediatric usability, (2) manufacturing-side process improvements that reduce cost or bioavailability variability, and (3) “life-cycle” reformulations that remain within the protected patent estate. The viable excipient strategy is driven by darunavir’s oral absorption profile, the need to control supersaturation risk, and the regulatory and IP constraints on composition-of-matter and formulation/method patents. The most material generic entry risk is tied to paragraph IV filings and Orange Book clearance for each specific strength and dosage form, while commercial timing is set by the expiration of New Chemical Entity and secondary formulation protections and any remaining regulatory exclusivities (Hatch-Waxman framework) for the specific product listed.
What excipients does PREZISTA use, and why do they matter for darunavir oral absorption?
Short answer: PREZISTA’s excipient system is built to support oral bioavailability of darunavir, manage physical stability in solid and suspension dosage forms, and enable manufacturability (compression properties, disintegration, wetting, and controlled solubilization).
Darunavir is a poorly water-soluble protease inhibitor. Excipient choices typically target three levers:
- Wetting and dispersion to reduce effective particle size at the GI surface.
- Solubilization and supersaturation management to maintain drug in solution without precipitation.
- Solid-state and mechanical performance to ensure batch-to-batch uniformity.
What excipient functions are most relevant to darunavir formulations?
Common high-impact excipient categories for poorly soluble drugs like darunavir:
- Surfactants / solubilizers to improve wetting and transient solubilization.
- Hydrophilic polymers to slow precipitation and stabilize supersaturation.
- Buffering agents to localize pH and maintain drug in a more soluble form in microenvironments.
- Disintegrants to accelerate tablet breakup and reduce drug agglomeration.
- Fillers and binders to preserve tablet strength and dissolution rate.
- Antioxidants and chelators where oxidative or moisture-related degradation is relevant to the specific product.
Why do excipient strategy and API selection intersect with IP risk?
Even when a reformulation uses similar excipient functions, it can trigger different protection risks. In practice, formulation IP can cover:
- specific excipient compositions and ranges
- particle size and polymorph handling (solid-state controls)
- manufacturing processes that create a distinct intermediate or final microstructure
- method-of-use and food-effect modifications (sometimes coupled with formulation)
So excipient strategy has to be engineered to stay outside composition-of-formulation claims for each listed PREZISTA product and strength.
What patents protect PREZISTA excipient compositions and formulation processes?
Short answer: The protectable landscape for PREZISTA typically includes (1) darunavir itself, (2) specific formulations (tablets, pediatric suspension), and (3) manufacturing or polymorph/particle-engineering methods. Excipient strategy is exposed to both “formula” claims (composition) and “manufacturing outcome” claims (method and product-by-process).
How formulation patents usually claim excipient systems
Formulation claims often use language like:
- “a pharmaceutical composition comprising darunavir and [named excipient(s)]”
- specific ratios or ranges (percent by weight)
- limitations on physical properties (dissolution profile or particle attributes)
- dosage-form-specific dependencies (immediate-release tablets, suspension viscosity targets)
Method claims may cover:
- granulation and mixing parameters
- milling and drying processes that influence solid-state properties
- coating or processing steps that control dissolution and stability
Which patent estate nodes create the highest commercial friction for reformulation?
- Secondary patents tied to specific strengths and dosage forms (tablet strengths and suspension versions) because generic conversion must match the exact listing or submit a Paragraph IV strategy per the listed drug.
- Food-effect and bioavailability-linked formulation claims, especially when marketed dosing requires co-administration constraints.
- Pediatric and suspension-specific claims, where dosing accuracy and solubilization/excipients are tightly linked to patient usability.
When does PREZISTA lose exclusivity by dosage form and strength?
Short answer: PREZISTA exclusivity timing is product-specific and depends on (1) the original approval timeline for darunavir and (2) subsequent secondary formulation or manufacturing patents listed in the Orange Book for each dosage form.
Because exclusivity outcomes depend on the exact FDA listing and the patent numbers tied to each listed drug, the practical approach for commercial planning is:
- treat each PREZISTA listing (tablet strength, suspension) as an independent “IP runway”
- map each Orange Book patent’s expiration and any pediatric exclusivity extensions
- add any market protection triggered by labeling-specific exclusivities
Commercial planning implication: excipient strategy often targets the “next formulation window,” not the API window.
What is the Orange Book status of PREZISTA, and how do those listings affect formulation options?
Short answer: Orange Book listings drive generic and reformulation clearance. If a formulation is not within the listed drug’s scope, it becomes an RLD or new ANDA target, shifting both regulatory and IP risk.
Why Orange Book mapping is decisive for excipient commercialization
For any excipient strategy that aims to commercialize as an ANDA or 505(b)(2) pathway, the key is:
- which patents are listed for the exact strength and dosage form
- whether there are active patent barriers (not expired)
- whether the applicant must carve around specific claims
How to think about generic versus reformulation using Orange Book listings
- ANDA generic route: must address all unexpired patents listed against the reference product for the specific listing.
- 505(b)(2) reformulation: often still faces Orange Book patent constraints on the reference product if it relies on the same active ingredient and dosing form.
- New dosage form: may shift to new RLD status, but formulation may still be constrained by relevant patents on darunavir compositions or methods.
What generic entry risks exist for PREZISTA, and which challenges are Paragraph IV driven?
Short answer: Generic risk concentrates on (1) patent-expiration calendars for each strength/dosage form and (2) Paragraph IV challenges that can force early settlement or launch.
How Paragraph IV changes excipient strategy
A Paragraph IV strategy typically requires:
- a formulation that clears non-expired patents (composition or method)
- proof of bioequivalence to the reference formulation
- control of dissolution behavior to match the reference product where excipient choices influence solubility and release
For excipient innovators, this changes the optimization target from “maximize performance” to “maximize performance under a specific IP clearance envelope.”
Settlement-driven dynamics
When Paragraph IV leads to settlement, it can lock out competing excipient strategies for a defined launch period. That affects:
- timing of a reformulation filing
- willingness to invest in bioequivalence work and pilot scale
- selection of route (ANDA vs 505(b)(2) vs new application)
Which formulations and delivery systems create the best commercial opportunities for darunavir excipient innovation?
Short answer: Commercial opportunity is highest where excipient-driven performance gaps exist versus reference products, particularly for:
- pediatric dosing (oral suspension and age-appropriate dose accuracy)
- high solubilization environments where precipitation control is needed
- manufacturability upgrades that reduce cost of goods and improve batch uniformity
- patient adherence improvements through viscosity and taste-masking systems (for suspension) and disintegration improvements (for tablets)
Pediatric oral suspension: the highest-value excipient segment
Suspensions create an excipient-driven “control surface” across:
- viscosity and pourability
- redispersibility after standing
- sedimentation rate
- stability of darunavir dispersion and prevention of caking
- taste and patient adherence
Commercially, this is a concentration point for IP because it often involves:
- specific dispersing agents
- wetting agents
- polymeric suspension aids
- stabilizers and preservatives
Tablet formulation: less visible, more defendable
Tablet excipient innovation is often less disruptive in the public label but can yield:
- better dissolution kinetics
- reduced variability
- lower manufacturing cost (excipients that reduce granulation burden)
- improved stability under real-world humidity and temperature
This segment can also be heavily patented via:
- specific binder/disintegrant combinations
- processing steps that create distinct granule properties
How does PREZISTA compare with other darunavir products and other HIV protease inhibitors on excipient strategy?
Short answer: PREZISTA’s excipient strategy reflects the need to manage darunavir’s solubility limits. Comparators in the protease inhibitor class (and within darunavir, across different marketed formats) differ in the balance of solubilizers, polymers, and processing aids used to reach comparable exposure.
What to look for in cross-product comparison for commercial leads
- dissolution profiles under biorelevant media
- presence and type of surfactants or precipitation inhibitors
- stability in suspension (for darunavir pediatric formats)
- handling properties (tablet hardness, friability, disintegration time)
These features often translate to different patent coverage and different generic design constraints.
What excipient innovation is likely to be patent-protectable for darunavir life-cycle management?
Short answer: Patent-protectable excipient strategies usually combine formulation composition with a measurable technical effect. The strongest commercially defensible strategies show:
- improved dissolution rate at clinically relevant pH
- controlled supersaturation and reduced precipitation
- improved stability (chemical and physical)
- improved suspension redispersibility and reduced sedimentation
- improved manufacturing robustness (yield, uniformity)
Where “functionally similar” excipient swaps fail commercially
Switching excipients without changing the release or absorption profile can still land the product inside a claim boundary. For IP planning, function is not enough. Protectability often requires:
- specific excipient selections and ratios
- tied performance outcomes
- defined manufacturing parameters
What manufacturing and scale-up risks are tied to PREZISTA excipients and how do they affect timelines?
Short answer: Excipient-driven risks are primarily linked to:
- granulation and compression behavior for tablets
- sedimentation and redispersibility for suspensions
- moisture uptake and solid-state stability for poorly soluble APIs
- batch-to-batch dissolution and bioequivalence consistency
Commercial timeline impact categories
- Bioburden control and preservative system for suspensions can dictate shelf life and packaging.
- Particle size and solid-state control for tablets affects dissolution and potency uniformity.
- Process reproducibility can become the gating factor for a 505(b)(2) or ANDA bridging package.
Where are the commercial opportunities outside the exact PREZISTA label: 505(b)(2), line extensions, and new dosage forms?
Short answer: Opportunities exist in line extensions that improve usability (pediatric dosing, simplified administration), enhance manufacturability (lower cost), or correct performance variability, provided the product design clears the relevant Orange Book patent estate.
High-leverage commercial tracks
- Pediatric suspension optimization: re-engineer viscosity and redispersibility while preserving dissolution and exposure targets.
- Solubility-enhanced tablet or granule engineering: controlled microenvironment dissolution systems.
- Stability-driven redesign: excipient systems that reduce moisture sensitivity and extend shelf life.
- Cost of goods reduction: reformulation using more economical excipients that maintain release.
Key Takeaways
- PREZISTA’s excipient strategy is centered on darunavir’s solubility and stability constraints, with formulation choices driving dissolution, precipitation control, and manufacturability.
- Excipient innovation that targets pediatric suspensions and solubility performance can create the strongest commercial upside, but it is also where formulation IP barriers are most likely.
- The decisive factor for commercialization is Orange Book and patent mapping per exact strength and dosage form; excipient strategy must align with patent clearance for the listed drug.
- Generic and reformulation opportunities depend on paragraph IV risk dynamics and timing of secondary formulation patents, which can be settled or extended through litigation.
- Manufacturability and scale-up risks tied to excipients (suspension rheology, tablet compression properties, humidity stability) can drive development timelines as much as bioequivalence.
FAQs
- What excipients help poorly soluble HIV protease inhibitors like darunavir maintain supersaturation without precipitation?
- Which darunavir dosage forms are most sensitive to formulation excipients: tablets or oral suspension?
- How does Orange Book listing by strength influence the feasibility of a reformulation strategy for darunavir?
- What formulation attributes are typically evaluated for bioequivalence in darunavir tablet reformulations?
- What manufacturing controls most often break reproducibility for darunavir suspensions during scale-up?
References (APA)
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- FDA. Drug Approval Package: PREZISTA (darunavir). U.S. Food and Drug Administration.
- Hatch-Waxman Act (Drug Price Competition and Patent Term Restoration Act of 1984). U.S. Congress.
- FDA. Guidance for Industry: Bioequivalence Studies for BE Products. U.S. Food and Drug Administration.
